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BACKGROUND. Although paclitaxel is used for hormone-resistant prostate cancer, relapse
definitely occurs later. Details of themolecularmechanism responsible for paclitaxel- resistance
remain unclear.
METHODS. We established paclitaxel-resistant cells, DU145-TxR and PC-3-TxR from parent
DU145 and PC-3. To characterize these cells, we examined cross-resistance to other anticancer
drugs. Expression of several potential genes that had been related to drug-resistance was
compared with parent cells by RT-PCR andWestern blotting. Methylation analysis of multiple
drug resistance (MDR1) promoterwas carried out using bisulfite-modifiedDNA fromcell lines.
Knockdown experiments using small interfering RNA (siRNA)were also performed to confirm
responsibility of drug-resistance. Finally, cDNA microarray was performed to quantify gene
expression in PC-3 and PC-3-TxR cells.
RESULTS. The IC50 for paclitaxel in DU145-TxR and PC-3-TxR was 34.0- and 43.4-fold higher
than that in bothparent cells, respectively. Both cells showed cross-resistance to somedrugs, but
not to VP-16 and cisplatin. Methylation analysis revealed that methylated CpG sites of MDR1
promoter in DU145 and PC-3 cells were demethylated in DU145-TxR cells, but not in PC-3-TxR
cells. KnockdownofP-glycoprotein (P-gp),whichwasup-regulated in resistant cells, byMDR-1
siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-
regulation of P-gp was not always main cause of paclitaxel-resistance. Microarray analysis
identified 201 (1.34%) up-regulated genes and 218 (1.45%) out of screened genes in PC-3-TxR.
CONCLUSIONS. Our data will provide molecular mechanisms of paclitaxel-resistance and
be useful for screening target genes to diagnose paclitaxel sensitivity. Prostate 67: 955–967,
2007. # 2007 Wiley-Liss, Inc.
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INTRODUCTION
Prostate cancer (PCa) is the most common malig-
nancy and the second most frequent cause of cancer-
related death ofmen in the United States [1]. Androgen
deprivation treatment is very effective for more than
80% of advanced PCa. More than half of those cases of
advanced PCa become resistant to deprivation treat-
ment after several years and then several other
*Correspondence to: Atsushi Mizokami, MD, PhD, Department of
Integrative Cancer Therapy and Urology, Kanazawa University
Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa,
Ishikawa 920-8640, Japan. E-mail: mizokami@med.kanazawa-u.ac.jp
Received 24 November 2006; Accepted 14 February 2007
DOI 10.1002/pros.20581
Published online 17 April 2007 in Wiley InterScience
(www.interscience.wiley.com).
 2007Wiley-Liss, Inc.
palliative treatments, such as estramustine phosphate
(EMP), steroids, are employed for these patients.
However, the results are very disappointing because
a half of those cases lead to death within a year or
2 years.
Recently, the taxanes [paclitaxel or docetaxel (DTX)]
with other agents, such as EMP or predonisone have
been used for hormone-resistant prostate cancer
(HRPC) and have shown good response [2–5]. Pacli-
taxel, which is purified from Taxus brevifolia, stabilize
microtubule and causes apoptosis [6]. The response
rates of taxane-based combination therapies are better
than combination therapies with other anticancer
agents. However, even HRPC treated with paclitaxel-
based chemotherapy also relapses as occurred using
other anticancer agents. Then the prognosis of the
patients after the relapse is extremely poor.
In order to investigate themechanisms of paclitaxel-
resistance, several paclitaxel-resistance cell lines have
been generated in ovarian cancer, breast cancer, and
lung cancer [7,8]. Some ofmajormechanisms of taxane-
resistance are overexpression of multiple drug resis-
tance (MDR1), andmultidrug resistance protein (MRP)
family [9]. Especially accumulation of P-glycoprotein
(P-gp) encoded from MDR1 might cause resistance of
several drugs in some cancers. The microtubule
dynamics may also be important for paclitaxel-resis-
tance because the target of paclitaxel is themicrotubule
[10]. As for the role of bcl-2 as a modulator of paclitaxel
sensitivity remains controversial. In human paclitaxel-
resistant hepatocellular carcinoma cells bcl-2 was
overexpressed [11]. Whereas bcl-2 expression was
consistently down-regulated in T47-D breast cancer
cells [12]. In PCa, although Bcl-2/Bcl-xL bispecific
antisense oligonucleotide also enhanced paclitaxel
chemosensitivity in PC-3 and LNCaP cells [13,14],
involvement to paclitaxel-resistance of Bcl-2/Bcl-xL in
PCa is not clear. Recently, cDNA microarray analyses
were performed in order to reveal the key genes that are
related with paclitaxel resistance. Not only MDR-1
gene but also Rho guanine dinucleotide phosphate
dissociation inhibitor beta (RhoGDI) and insulin-like
growth factor-binding protein 3 (IGFBP-3) were up-
regulated in paclitaxel-resistant ovarian cancer cell
lines [15]. Villeneuve et al.[16]described that 1.9% of
1,728 geneswere regulated in paclitaxel-resistantMCF-
7 breast cancer cells. Thus it is very important to know
the mechanisms of paclitaxel-resistance in PCa.
In the present study, we established two paclitaxel-
resistant cell lines from androgen-independent DU145
and PC-3 PCa cell lines by increasing concentration of
paclitaxel gradually. Although both cell lines showed
resistance to paclitaxel over 30 timesmore than parents
cells and cross-resistance to other anticancer drugs, the
mechanism of resistance was different.
MATERIALSANDMETHODS
Cell Culture andCell ProliferationAssay
DU145 and PC-3 cells purchased from American
type culture collection were cultured in Dulbecco’s
modified Eagle medium (DMEM) and RPMI1640
containing 5% fetal calf serum (FCS) and penicillin/
streptomycin (Invitrogen, CA, USA). Cell growth
inhibition assay was preformed by plating 1 105 cells
on 6-well plates. Twenty-four hours later, cells were
treated with the indicated concentration of anticancer
agents, and cultured for an additional 48 hr. At the end
of the culture period, the cells were trypsinized and
counted with a hemocytometer.
Establishmentof Paclitaxel-resistant DU145 and
PC-3 Cell Lines
Paclitaxel-resistant cancer cells were obtained by
stepwise increased concentrations of paclitaxel. DU145
and PC-3 cells maintained as described above were
incubated with 10 nM paclitaxel for 2 days. Then the
medium was changed to fresh one without paclitaxel
and cells were cultured cells grow well. Whenever we
subcultured, the cells were incubated with gradual
increasing concentration of paclitaxel for 2 days and
cultured without paclitaxel until cells growwell. Some
aliquots of the cells were stored whenever we sub-
cultured it. When cells were killed by increased
paclitaxel, the aliquots were subcultured again and
lower concentration of paclitaxel was used for treat-
ment. Cells that grew at themaximum concentration of
paclitaxel were stored for further analyses. For main-
tenance of paclitaxel-resistant cells, 10 nM paclitaxel
was added into the normal medium every time.
RNA extraction and RT-PCR. Twenty-four hours
after plating of 1 106 DU145 or PC-3 cells, total RNA
was purified with RNeasy mini kit (Qiagen, Maryland,
USA). Complementary DNA (cDNA) was made by
reverse-transcription (RT) of 1 mg each total RNAusing
ThermoScript RT-PCR system (Invitrogen). Each
cDNA sample was amplified with ExTaq (Takara,
Japan). PCR reactions for indicated genes were carried
out using the following forward (F) and reverse (R) in
Table I. Each of the amplified PCR products was
determined by electrophoresis on an 1.5% agarose gel.
Western blot analysis. Twenty-four hours after plat-
ing 1 106 DU145, DU145-TxR or PC-3, and PC-3-TxR
cells on 6 cm dishes in DMEM-5% FBS, the cells were
lysed with 200 ml hypotonic buffer (20 mM Tris-HCl
(pH 7.6), 10 mM NaCl, 1 mM MgCl2, and 0.5% NP-40)
and themembrane and cytosol fractions were collected
by centrifugation as described previously [17]. To
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extract nuclear protein, the centrifuged pellet after
separating cytosol fraction was lysed with 50 ml
hypertonic buffer (20 mM Tris-HCl (pH 7.6), 0.42 M
NaCl, 1 mM EDTA, and 0.5% NP-40) and nuclear
fraction were collected by centrifugation. To extract
whole cell protein, cells were lysed with hypertonic
buffer directly. Fiftymicrograms of cytosol protein, 50 mg
of whole cell protein, or 10 mg of nuclear protein was
loaded in each lane of 7.5 or 12.5%ReadyGel J (Bio-Rad,
NY), subjected to electrophoresis, then electrotrans-
ferred to a PVDF membrane (Bio-Rad). The immobi-
lized proteins were incubated with primary antibody,
P-gp (rabbit polyclonal IgG, 200-fold dilution; Santa
Cruz, CA), YB-1 (goat polyclonal IgG, 200-folddilution;
Santa Cruz), or GAPDH (rabbit polyclonal IgG, 1,000-
fold dilution; Trevigen, MD). The presence of primary
antibody was visualized by Super signal west pico
luminol/enhancer solution (Pearce, IL).
Methylation analysis of MDR1 promoter. Genomic
DNA from PC-3, PC-3-TxR, DU145, and DU145-TxR
was purified using Blood and cell cultureDNAmini kit
(Quiagen) 24 hr after 5 105 cells were plated on 6 cm
dish. Onemicrogram of DNAwas subjected to sodium
bisulfite modification kit (BisulFast DNAModification
Kit, Toyobo, Osaka, Japan). MDR-1 (223 bp) promoter
region (183 toþ40 of transcription initiation site) was
amplified from bisulfite-modified DNA as described
by Enokida et al. [18,19]. The amplified DNA was
further amplified using methylation-specific primer
(MSP) or unmethylation-specific primer (USP) after
100-fold dilution of the amplified DNA [19]. PCR
reaction was modified to 948C 15 s, 708C 30 s, 728C and
20 cycles forMSP primers and 948C 15 s, 688C 30 s, 728C
and 20 cycles for USP primers. Then DNA sequence
analysiswas also carried out using the amplified 223 bp
PCR products.
Small interfering RNA transfection. MDR-1 small
interfering RNA (siRNA), lamina/C siRNA, non-
targeting siRNA were purchased from Dharmacon
(Lafayette, CO). After 3 104 DU145-TxR and PC-3-
TxR cells or 3 105 those cells were cultured on 24-well
plates or in 6-well plates for total RNA purification or
for protein extraction, respectively, cells were trans-
fected with 0, 10, 20, or 30 nM MDR-1 siRNA, 30 nM
lamina/C siRNA, and 30 nM non-targeting siRNA by
X-treme GENE siRNA Transfection Reagent (Roche).
Forty-eight hours after transfection, total RNA and
proteinwas extracted. In order to see the effect of siRNA
on drug resistance, cells were transfected with 30 nM
MDR-1 siRNA or non-targeting siRNA 24 hr after
plating on 24-well plates. Twenty-four hours later cells
were treated with 0, 1, 3, 10, 30, 100, 300, and 1,000 nM
paclitaxel and cultured for 48 hr. Then the cells were
trypsinized and counted with a hemocytometer.
cDNAMicroarrayAnalysis
Twenty-four hours after plating of 5 105 PC-3 cells,
total RNAwaspurifiedwithRNeasymini kit (Qiagen,).
RNA samples were sent to Hokkaido system science
(Sapporo, Japan) and analyzed byAgilent technologies
(human 1A microarray kit).
RESULTS
Establishmentof Paclitaxel-resistant Cell Lines
When we examined the sensitivity for paclitaxel
of parent DU145 and PC-3 cells, IC50 values of
these cells were 11.3 and 5.0 nM, respectively
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TABLE I. The PrimersUsed for RT-PCRAnalysis
Gene Forward Reverse
GAPDH 50-GACCACAGTCCATGCCATCA-30 50-TCCACCACCCTGTTGCTGTA-30
MDR-1 50-ATGCTCTGGCCTTCTGG ATG GGA-30 50-ATGGCGATCCTCTGCTTCTGCCCA C-30
MRP-1 50-GCATGA TCCCTGAAGACGA-30 50-TAGAGCTGG CCCTTGTACTC-30
MRP2 50-TAGAGCTGGCCCTTGTACTC-30 50-TCAACTTCCCAGACATCCTC-30






Caspase-8 50-ACTTCAGACACCAGGCAGGGC T-30 50-GCCCCTGCATCCAAGTGTGTTC-30
Bcl-2 50-ATGTCCAGCCAGCTGCACCTGAC-30 50-GCAGAGTCTTCAGAGACAGCCAGG-30
Bax 50- GCTTCAGGGTTTCATCCAGG-30 50-AAAGTAGGAGAGGAGGCCGT-30
c-jun 50- GGAAA GACCTTCTATGACGATGC -30 50-GAACCCCTCCTGCTCATCTGT CAC-30
YB-1 50-GACTGCCATAGAGAATAACCCCAG-30 50-CTCTCTAGGCTGTTTTGGGCGAGGA-30
Sp-1 50-GCTGCCGCTCCCAACTTACA-30 50-ATCGTGACTGCCTGAGAGCT-30
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(Tables II and III). We established paclitaxel-resistant
DU145 (DU145-TxR) and PC-3 (PC-3-TxR) cells by
stepwise exposure method (from 10 nM paclitaxel) for
9 and 15 months, respectively. Cell growth inhibi-
tion assay demonstrated that these DU145-TxR and
PC-3-TxR cells become 34.0-fold (IC50: 384.2 nM) and
43.4-fold (IC50: 217.1 nM)more paclitaxel resistant than
parent cells (Tables II and III and Fig. 1). We also
compared the cross-resistance to other anticancer
drugs [EMP, vinblastin (VBL), doxorubicin (DOX),
DTX, VP-16, and cisplatin] between parent and
paclitaxel-resistant cells (Figs. 2 and 3, Tables II
and III). Both of DU145-TxR and PC-3-TxR cells
showed almost same cross-resistance to EMP, VBL,
DOX, and DTX. However, cross-resistance to cisplatin
and VP-16 was hardly observed.
Expression of Several Potential
ChemoresistantGenes
Cellular mechanisms of drug resistance include
in decreasing intracellular drug concentrations by
increased efflux or decreased influx. The drug distribu-
tion in anorganism ishighlydependent on transporters
which play a role in absorption and elimination. P-gp
and MRP which belong to the ATP-binding cassettes
(ABC) family are well-known typical transporters. We
evaluated the expression ofMDR-1 andMRP1 toMRP7
of DU145-TxR and PC-3-TxR cells by RT-PCR. Only
MDR-1 mRNA was overexpressed in both cells
(Fig. 4A). Since MDR-1 mRNA was overexpressed in
both cells, we confirmed the expression of P-gp which
was encoded from MDR-1 mRNA. P-gp as well as
MDR-1 mRNA was overexpressed in DU145-TxR and
PC-3-TxR cells but not in parent cells (Fig. 4B). More-
over, the level of P-gp in DU145-TxR cells was more
expressed than PC-3 cells. Since the cell death by
paclitaxel is associated with apoptosis, we also com-
pared the expression of major apoptosis-related genes,
Bcl-2, Bax, Fas, and Capase-8 in these cells. However,
expression level of all of these genes was not changed
between parent and resistant cells (Fig. 4C).
MechanismsofMDR1Overexpresssion in
DU145-TxR and PC-3-TxRCells
One of mechanisms by which of MDR-1 is over-
expressed in paclitaxel-resistant cells is the induction
by Y-box-binding protein 1 (YB-1). YB-1 is mainly
located in the cytoplasm [20]. Once cells are exposed to
UV irradiation and anticancer drugs, such as paclitaxel,
YB-1 tanslocates into nucleus, bind to a cis-acting
element of the MDR-1 promoter, and induce MDR-1
mRNA expression [21]. In order to see the nuclear
localization of YB-1 protein, we performed Western
blot analysis. The YB-1 protein level in nucleus was
about three times higher in DU145-TxR cells than in
DU145 cells and itwas almost at the same level between
PC-3 and PC-3-TxR cells (Fig. 5A). Nuclear localization
of YB-1 was less dramatic compared to the MDR-1
expression in paclitaxel-resistant cells.
Next, we investigated methylation status of CpG
sites at the MDR1 promoter region because some
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Fig. 1. Establishment of paclitaxel-treated cell lines. DU145 (A), paclitaxel-resistant DU145-TxR (B), PC-3 (C), and paclitaxel-resistant
PC-3-TxR(D) cellswereexposedwithindicatedconcentrationsofpaclitaxel for24hr andcounted2days afterexposure.
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groups reported inverse correlation between methyla-
tion and MDR1 expression in [19,22,23]. Since DU145-
TxR and PC-3-TxR cells overexpressed MDR1 mRNA
compared to parent cells, we expected that paclitaxel-
resistance might cause demethylation of CpG sites at
MDR1 promoter. AlthoughMSP published by Enokida
et al. detected PCR products from bisulfite-modified
DNA in both parent cells and paclitaxel-resistant cells,
USP detected stronger PCR band in DU145-TxR cells
than inDU145 cells, suggesting thatMDR1 promoter in
DU145-TxR cells is lessmethylated than inDU145 cells.
However, USP did not detect PCR band in PC-3-TxR
cells compared to PC-3 (Fig. 5B). To further confirm the
methylated CpG site at the MDR1 promoter, we
performed DNA sequence analysis using bisulfite-
modified DNA. The MDR1 promoter region of DU145
cells was methylated at the CpG sites of 134, 105,
59, 56, 51, 34, and 29 of the transcription
initiation site. The MDR1 promoter region of DU145-
TxR cells was methylated only at the CpG site of -105
The Prostate DOI 10.1002/pros
Fig. 2. Cross-resistance of DU145 and DU145-TxR cells. DU145
and DU145-TxR cells were exposedwith indicated concentrations
ofEMP, docetaxel (DTX), vinblastin (VBL), doxorubicin (DOX), cis-






TABLE III. IC50 Value of PC-3 and PC-3-TxRCells
Drug PC-3 PC-3-TxR Fold difference
PTX (nM) 5.00 217.1 43.4
EMP (mM) 8.57 33.0 3.85
DTX (nM) 3.67 28.2 7.68
VBL (nM) 8.00 27.4 2.43
DOX (nM) 121.3 1,218.2 10.0
VP-16 (mM) 4.40 5.95 1.35
CDDP (mM) 1.47 1.66 1.13
TABLE II. IC50 Value ofDU145 andDU145-TxRCells
Drug DU145 DU145-TxR Fold difference
PTX (nM) 11.3 384.2 34.0
EMP (mM) 15.1 49.6 3.28
DTX (nM) 8.30 55.6 6.70
VBL (nM) 14.1 40.8 2.89
DOX (nM) 17.5 61.1 3.49
VP-16 (mM) 0.83 1.10 1.33
CDDP (mM) 1.32 1.97 1.49
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(data not sown). Especially, the important region for
MDR1 transcriptional regulation that included a G-box
(59, 56, and 51) [24] was demethylated in DU145-
TxR cells (Fig. 5C). This demethylation of MDR1
promoter in DU145-TxR cells was coincident with the
enhanced MDR1 expression. Whereas DNA sequence
analysis of the amplified PCR product showed that the
MDR1 promoter regions of PC-3 and PC-3-TxR cells
were methylated at the CpG sites of 134, 110, 59,
51,34, and29 and at the CpG sites of,110,105,
59,56,51, and29, respectively. Much difference
was not observed in the methylated sites and the
number between PC-3 and PC-3-TxR promoter region.
Recoveryof Paclitaxel SensitivitybyMDR-1
Knockdown
In order to investigate if MDR-1 mRNA overexpres-
sion in TxR cells is the main cause of paclitaxel
resistance, we knocked-down the MDR-1 mRNA by
MDR-1 siRNA. Ten to thirty nanometer MDR-1 siRNA
down-regulatedMDR-1mRNA inDU145-TxR andPC-
3-TxR cells 48 h after transfection (Fig. 5A and C). Non-
targeting siRNA and laminin siRNA failed to inhibit
MDR-1 mRNA expression. MDR-1 mRNA down-
regulation by MDR-1 siRNA treatment also inhibited
the expression of P-gp protein.
Since MDR-1 siRNA down-regulated P-gp, we
confirmed if MDR-1 down-regulation could restore
paclitaxel sensitivity. As shown in Table IV and
Figure 5B and D, IC50 of in parent DU145 and PC-3
cells was not changed when non-target (NT) siRNA or
MDR-1 siRNA was transfected. Transfection with
MDR-1 siRNAintoDU145-TxR cells after 48hr restored
paclitaxel sensitivity compared to transfectionwithNT
siRNA (Fig. 6B). IC50 of paclitaxel of DU145-TxR was
reduced from 537.9 nM to 60.8 nM and recovery ratio
became 88.7% 48 hr after transfection (Table IV).
Whereas transfection with MDR-1 siRNA into PC-3-
TxR cells hardly changed paclitaxel sensitivity. IC50 of
paclitaxel of PC-3-TxRwas reducedonly from198.4 nM
to 140.6 nMand recovery ratio became229.1% (Table IV
and Fig. 6D) sensitivity.
Mechanismsof Paclitaxel Resistance in
PC-3-TxRCells
Although P-gp overexpression played important
role on paclitaxel resistance in DU145-TxR cells, this
was not an important factor in PC-3-TxR cells. There
should be P-gp-independent pathway to become
paclitaxel-resistance. In order to identify the genes that
are associatedwith onpaclitaxel resistance inPC-3-TxR
cells, we performed cDNA microarray using mRNA
from parent PC-3 and PC-3-TxR cells and compared
differentially expressed genes as described inMaterials
and Methods. Approximately 15,000 genes were
screened by microarray analysis. two hundred and
one (1.34%) of screened genes were inducedmore than
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Fig. 4. Expressionofvariousdrug-resistance-relatedgenesinparentandpaclitaxel-resistantcells. (A)RT-PCRofMDRandMRP1-7mRNAin
DU145,DU145-TxR,PC-3,andPC-3-TxRcells.AftermRNAwaspurifiedfromthesecells,RT-PCRwasperformedusingprimersasdescribedin
Table1. (B)ExpressionofP-gp.Cellswereculturedfor12hin thepresenceofindicatedconcentrationofDHTorAdiolandharvested.Membrane
and cytosol proteinwere extracted as described in Materials and Methods and loaded on an 7.5% SDS-polyacrylamide gel for Western blot
analysis. After proteinwas transferred to PVDF-membrane, anti-P-gp antibody and anti-GAPDH antibody were employed for detection of
170kDaP-gp and 37kDaGAPDHprotein, respectively. (C) RT-PCRofbcl-2, Bax,Fas, andcapase-8mRNAinDU145,DU145-TxR,PC-3, and
PC-3-TxRcells.
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two-fold and 218 (1.45%) of genes were reduced more
than two-fold in PC-3-TxR cell line compared with
parent PC-3 cell line. TablesVandVIdescribe themajor
30 genes that showed up-regulated and down-regu-
lated expression in PC-3-TxR cells comparedwith PC-3
cells. As we confirmed in Figure 4, MDR-1 genes was
up-regulated to 6.0-fold in PC-3-TxR cells. Some
microtubule-related genes, tubuline b6, b2, and b4,
wereup-regulated to 3.5-, 2.2-, and2.1-fold inPC-3-TxR
cells, respectively. Calcium is an important factor
that is associated with microtubule polymerization.
Calcium-binding protein, S100A9 and S100A8 were
The Prostate DOI 10.1002/pros
Fig. 5. Expression ofYB-1protein andmethylation status ofMDR1promoter. (A)Westernblottingof YB-1protein.Whole cell protein and
nuclearproteinwereextractedasdescribedinMaterialsandMethodsandloadedona12.5%SDS-polyacrylamidegelforWesternblotting.After
proteinwas transferred to PVDFmembrane, anti-YB-1or GAPDH antibody was employed for detection of 35.4 or 37 kDaYB-1or GAPDH
protein, respectively.B: Detection of methylated and unmethylated promoter of MDR1genes.USP and MSP were employed for detection
of unmethylated and methylated MDR1 promoter after the 223 bp MDR1 promoter region was amplified from bisulfite-modified DNA.
C: Bisulfite-modified DNA sequence of MDR1promoter.The sequences of bisulfite-modified MDR1promoter regions fromDU145,DU145-
TxR,PC-3, andPC-3-TxRcellswere shownfrom65to21of transcriptioninitiation site.Underlines anddoubleunderline showmethylated
CpGsites andG-box,respectively.
TABLE IV. IC50 Value of Paclitaxel in iMDR-1-Transfected TxRCells
Transfected cells IC50 (nM) Relative resistant ratio Recovery ratio
DU145 (NT siRNA) 9.74 1.0
DU145 (iMDR-1) 9.11 0.94 6%
DU145-TxR (NT siRNA) 537.9 55.2
DU145-TxR (iMDR-1) 60.8 6.24 88.7%
PC-3 (NT siRNA) 10.5 1.0
PC-3 (iMDR-1) 10.0 0.95 5%
PC-3-TxR (NT siRNA) 198.4 18.9
PC-3-TxR (iMDR-1) 140.6 13.4 29.1%
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down-regulated to 4.34- and 2.56-fold in PC-3-TxR
cells, respectively. Other calcium-related genes, tumor-
associated calcium signal transducer 1 (TACSTD1),
S100P, and S100A2 mRNA were also down-regulated
in PC-3-TxR cells. MMP-1 that is related with cancer
invasion is overexpressed in multiple drug-resistant
cell lines [25]. We also observed overexpression of
MMP-1 in PC-3-TxR cells (4.77-fold).
DISCUSSION
In order to elucidate the mechanisms of paclitaxel -
resistant in hormone refractory PCa, we established
two paclitaxel-resistant cell lines from androgen-
independent cell lines. Several potential mechanisms
have been proposed for resistance to taxans. The result
that cross-resistance to cisplatin and VP-16 was not
observed in both paclitaxel-resistant cell lines indicates
that resistance to paclitaxel is resulted from different
pathways from resistance to cisplatin and VP-16.
Although paclitaxel induces apoptosis, we could not
detect differences of expression in apoptosis-related
genes, such as bcl-2, bax, caspase 8 between parent cells
and TxR cells. One of major mechanisms of paclitaxel-
resistance is overexpression of P-gp [9]. The MDR-1
overexpression was the important factor as a respon-
sible gene when DU145 cells became paclitaxel resis-
tance. Since MDR-1 siRNA almost restored paclitaxel
sensitivity in DU145-TxR cells, P-gp overexpression is
the main reason of paclitaxel resistance in this cell line.
Our results showed that one ofmainmechanisms by
which of MDR-1 was overexpressed in paclitaxel-
resistant DU145 cells was the demethylation of CpG
sites at the MDR1 promoter region. Originally CpG
sites at the MDR1 promoter region in parent DU145
cells were hypermethylated [19]. Because it is rare, as
for the necessity of MDR1, expression of MDR1 is
inhibited for cancer cell by methylation of MDR1
promoter. However, when cells can leave damage by
paclitaxel, demethylation of MDR1 promoter, espe-
cially G-box that includes Sp1-binding site and EGR-1-
binding site and is very important for transcription [24],
is promoted and induces expression of MDR1 so that
cell themselves survives it, then cells may be going to
remove paclitaxel from intracellular. However, it
remains unclear why PC-3-TxR cells overexpressed
The Prostate DOI 10.1002/pros
Fig. 6. PaclitaxeliniMDR-1transfectedTxRcells.AandC:Forty-eighthoursafter transfectionwith0,10,20,or30nMMDR-1siRNA,30nM
LaminA/C siRNA (La), and 30 nM non-targeting siRNA (La), total RNA andproteinwas extracted according to theMaterials andMethods.
BandD: Inorder to see theeffectof siRNAondrugresistance,cellswere transfectedwith30nMMDR-1siRNAornon-targeting siRNA24hr
afterplatingon24-wellplates.Twenty-fourhoursafter transfectionwith30nMnon-targetingiRNAoriMDR-1,cellsweretreatedwith0,1,3,10,
30,100, 300, and1,000 nM paclitaxel and cultured for 48 hr.Then the cells were countedwith a hemocytometer.The data representmean of
triplicateexperiments andthebars showSD.ThedataweredescribedinTable1V.
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TNS NM_022648 704 97 7.23 Tensin
ABCB1 NM_000927 5,902 980 6.02 ATP-binding cassette, subfamily B (MDR/TAP)
LAMA4 NM_002290 10,609 1,991 5.33 Laminin, alpha 4 (LAMA4)
IGSF4 NM_014333 2,586 486 5.32 Immunoglobulin superfamily, member 4
CD33L3 AK092746 22,410 4,403 5.09 cDNA FLJ35427 fis, clone SMINT2001731
MMP1 NM_002421 10,946 2,293 4.77 Matrix metalloproteinase 1 (interstitial collagenase)
TIMP4 NM_003256 2,786 644 4.33 Tissue inhibitor of metalloproteinase 4
AUTS2 NM_015570 821 199 4.12 Autism susceptibility candidate 2
PLA2G7 NM_005084 4,353 1,068 4.08 Phospholipase A2, group VII (platelet-activating
factor acetylhydrolase, plasma)
ROBO4 NM_019055 2,058 508 4.05 Roundabout homolog 4, magic roundabout (Drosophila)
IL1RL1 NM_016232 1,121 286 3.92 Interleukin 1 receptor-like 1 (IL1RL1), transcript
variant 1
POU4F3 NM_002700 557 148 3.76 POU domain, class 4, transcription factor 3
SLC35F2 NM_017515 31,443 8,611 3.65 Solute carrier family 35, member F2
FZD4 NM_012193 9,899 2,791 3.55 Frizzled homolog 4 (Drosophila) (FZD4)
MGC4083 NM_032525 20,402 5,787 3.53 Tubulin beta MGC4083
TFPI2 AK092499 21,336 6,056 3.52 cDNA FLJ35180 fis, clone PLACE6014882, similar to
Tissue Factor pathway inhibitor 2
CHKA NM_001277 893 262 3.41 Choline kinase
PFTK1 NM_012395 2,295 705 3.26 PFTAIRE protein kinase 1
BNIP3 NM_004052 26,713 8,310 3.21 BCL2/adenovirus E1B 19 kDa interacting protein 3
C14orf149 NM_144581 25,746 8,094 3.18 Hypothetical protein FLJ25436
H19 AK056774 2,557 815 3.14 cDNA FLJ32212 fis, clone PLACE6003399, weakly
similar to SPIDROIN 1
MGC2574 NM_024098 24,317 7,812 3.11 Hypothetical protein MGC2574
LOC114990 NM_138440 1,953 647 3.02 Hypothetical protein BC013767
MGC10981 BC004397 776 259 2.99 Hypothetical protein MGC10981
PRSS11 NM_002775 14,523 5,115 2.84 Protease, serine, 11 (IGF binding)
DPYSL4 NM_006426 776 274 2.83 Dihydropyrimidinase-like 4
GPR56 NM_005682 32,764 11,683 2.80 G protein-coupled receptor 56
BAG3 NM_004281 3,952 1,425 2.77 BCL2-associated athanogene 3
SC5DL BC012333 4,652 1,685 2.76 Sterol-C5-desaturase (ERG3 delta-5-desaturase
homolog, fungal)-like
C10orf125 NM_198472 3,036 1,101 2.76 FLJ26016 protein (FLJ26016)
MTVR1 NM_152832 8,897 3,302 2.69 Mouse mammary turmor virus receptor homolog 1
GPR4 NM_005282 1,507 565 2.66 G protein-coupled receptor 4
FAHD1 NM_031208 6,677 2,517 2.65 Hypothetical protein DKFZp566J2046
FLJ37078 NM_153043 395 149 2.64 Hypothetical protein FLJ37078
POLA2 NM_002689 10,368 3,935 2.64 Polymerase (DNA-directed), alpha (70kD)
LOC201194 AK022617 540 207 2.61 cDNA FLJ12555 fis
MGC16291 NM_032770 3,167 1,228 2.58 Hypothetical protein MGC16291
ESM1 NM_007036 7,643 2,966 2.58 Endothelial cell-specific molecule 1
CDCA5 NM_080668 15,949 6,219 2.56 Cell division cycle associated 5
DGAT2 NM_032564 530 207 2.56 Diacylglycerol O-acyltransferase homolog 2
SLC35F2 AK128062 2,548 998 2.55 cDNA FLJ46182 fis
LOC201194 AK022617 488 192 2.54 cDNA FLJ12555 fis, clone NT2RM4000764
ESM1 NM_007036 6,500 2,560 2.54 Endothelial cell-specific molecule 1
LOC201194 AK022617 553 218 2.53 cDNA FLJ12555 fis, clone NT2RM4000764
EHBP1L1 AL834433 2,554 1,008 2.53 cDNA DKFZp762C186
FANCA NM_000135 874 348 2.51 Fanconi anemia, complementation group A
ESM1 NM_007036 10,124 4,042 2.50 Endothelial cell-specific molecule 1 (ESM1), mRNA
The Establishmentof Two Paclitaxel-Resistant Prostate CancerCell Lines 963
The Prostate DOI 10.1002/pros











IL23A NM_016584 988 16,873 17.07 Interleukin 23, alpha subunit p19
CALB1 NM_004929 482 7,509 15.57 Calbindin 1, 28 kDa
CTEN NM_032865 591 6,318 10.69 C-terminal tensin-like
PLAC8 NM_016619 290 2,886 9.95 Placenta-specific 8
LXN NM_020169 214 1,957 9.13 Latexin protein
CDH1 NM_004360 626 4,957 7.92 Cadherin 1, type 1, E-cadherin (epithelial)
S100A2 NM_005978 2,579 17,878 6.93 S100 calcium-binding protein A2
KLK6 NM_002774 140 930 6.66 Kallikrein 6 (neurosin, zyme)
IL6 NM_000600 1,592 10,288 6.46 Interleukin 6 (interferon, beta 2)
LCN2 NM_005564 1,277 7,457 5.84 Lipocalin 2 (oncogene 24p3)
IL13RA2 NM_000640 143 752 5.26 Interleukin 13 receptor, alpha 2
CSF2 NM_000758 1,595 8,099 5.08 Colony stimulating factor 2 (granulocyte-macrophage)
CD33 NM_001772 205 1,037 5.07 CD33 antigen (gp67)
SERPINB4 NM_002974 708 3,545 5.01 Serine (or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 4
CYP1B1 NM_000104 3,090 15,173 4.91 Cytochrome P450, family 1, subfamily B, polypeptide 1
NOX5 NM_024505 1,707 7,840 4.59 NADPH oxidase, EF hand calcium-binding domain 5
CRB3 NM_174882 390 1,774 4.55 Crumbs homolog 3 (Drosophila) (CRB3)
NMES1 NM_032413 3,567 16,181 4.54 Normal mucosa of esophagus specific 1
PTAFR NM_000952 297 1,344 4.53 Platelet-activating factor receptor
THBD NM_000361 165 749 4.53 Thrombomodulin
SAT NM_002970 2,227 10,029 4.50 Spermidine/spermine N1-acetyltransferase
FXYD6 NM_022003 594 2,674 4.50 FXYD domain containing ion transport regulator 6
SAA1 NM_000331 410 1,834 4.47 Serum amyloid A1 (SAA1)
TACSTD1 NM_002354 4,722 21,027 4.45 Tumor-associated calcium signal transducer 1
IL1F7 NM_014439 1,532 6,811 4.45 Interleukin 1 family, member 7 (zeta)
ADMP NM_145035 504 2,213 4.39 ADMP
IFI27 NM_005532 211 915 4.35 Interferon, alpha-inducible protein 27
S100A9 NM_002965 2,678 11,624 4.34 S100 calcium-binding protein A9 (calgranulin B)
AY358920 AY358920 216 931 4.31 Clone DNA129549 ALGV3072 (UNQ3072)
IFI27 NM_005532 139 594 4.27 Interferon, alpha-inducible protein 27
ALOX5AP NM_001629 2,028 8,503 4.19 Arachidonate 5-lipoxygenase-activating protein
AREG NM_001657 1,461 6,122 4.19 Amphiregulin (schwannoma-derived growth factor)
ANKRD1 NM_014391 131 545 4.16 Ankyrin repeat domain 1 (cardiac muscle)
SGNE1 NM_003020 748 3,076 4.11 Secretory granule, neuroendocrine protein 1 (7B2 protein)
IFITM1 NM_003641 698 2,783 3.99 Interferon induced transmembrane protein 1 (9–27)
FCGR2C NM_201563 198 785 3.96 Fc fragment of IgG, low affinity IIc, receptor for (CD32)
FLJ31204 NM_174912 150 584 3.89 Hypothetical protein FLJ31204
S100P NM_005980 2,465 9,570 3.88 S100 calcium-binding protein P
HIST1H1C NM_005319 3,943 14,847 3.77 Histone 1, H1c
CD33 AY162464 500 1,875 3.75 Sialic acid-binding immunoglobulin-like lectin 3
CXCL2 NM_002089 4,477 16,726 3.74 Chemokine (CXC motif) ligand 2
CXCL3 NM_002090 4,728 17,552 3.71 Chemokine (CXC motif) ligand 3
SERPINB3 NM_006919 1,206 4,461 3.70 Serine (or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 3
CCL20 NM_004591 844 3,109 3.68 Chemokine (CC motif) ligand 20
KLF5 NM_001730 2,148 7,908 3.68 Kruppel-like factor 5 (intestinal)
AMIGO2 NM_181847 852 3,108 3.65 Homo sapiens amphoterin induced gene 2
AIM2 NM_004833 232 845 3.64 Absent in melanoma 2
THC1991570 THC1991570 1,416 5,074 3.58 AY140952 G-protein coupled receptor GPR110
SAA2 NM_030754 450 1,591 3.54 Serum amyloid A2
TGFA NM_003236 1,294 4,544 3.51 Transforming growth factor, alpha
FGFBP1 NM_005130 1,619 5,680 3.51 Heparin-binding growth factor-binding protein
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MDR1 mRNA compared to PC-3 cells although the
expression level in PC-3-TxR cells was lower than in
DU145-TxR cells. It will be very interesting to study
why paclitaxel exposure causes demethylation of the
MDR1 promoter region of DU145 cells.
Inhibition of MDR-1 hardly restored resistance in
PC-3-TxR although PC-3-TxR cells overexpressed P-gp
compared to parent PC-3 cells. Only by overexpression
of p-gp, there is not explanation of the mechanism
that PC -3 cells become paclitaxel resistance. Other
mechanisms should be involved in paclitaxel-resis-
tance in PC-3-TxR cells. Lin et al.[26] demonstrated
thatDOX resistance rat PCa cell line expressedmore Id-
1, MIF, and GSTpi mRNA than parent cell line . They
also showed that overexpression of Id-1 caused
paclitaxel-resistance in the cell line.However,we could
not detect thedifference of Id-1 expression betweenPC-
3 and PC-3-TxR cells although Id-1 mRNA was
temporally down-regulated by paclitaxel treatment in
PC-3 cells.
In order to investigate what genes are involved in
paclitaxel resistance, we compared gene expression
profile between PC-3 and PC-3-TxR cells. To the best of
our knowledge, this is the first report that compared
gene expression profile about paclitaxel-resistance in
hormone refractory PCa cell line. Expressions of many
genes were also altered in paclitaxel-resistant breast
cancer cells [16]. Expression patterns were similar in
some of these genes, such as MDR1 and S100P.
However, those in PC-3-TxR cells were different from
breast cancer cells, suggesting that different mechan-
isms are involved in becoming paclitaxel-resistance in
different cancers.
Paclitaxel shows the effect as an anticancer drug by
stabilizing polymer of microtubule [27]. Alterations of
microtubule formation in resistant cells is also impor-
tant factors [10,28]. Li et al.[29] demonstrated by
microarray analysis that taxotere regulatedmanygenes
including microtubule, apoptosis, and cell cycle-
related genes in PCa cell lines, PC-3 and LNCaP cells.
Especially, microtubule-related genes are down-regu-
lated in those cells. They treated cells with taxotere
transiently and compare the regulated genes before
and after treatment. Down-regulated genes after treat-
mentmay be the geneswhich, as a result of having been
impaired, were inhibited by taxotere. Or up-regulated
genes may be the genes which, as a result, are elevated
when apoptosis by taxotere is induced. Ranganathan
et al.[30] demonstrated that increase in tubulin bIII
(nine-fold) and bIVa (five-fold) were observed in
DU145 cells that became paclitaxel-resistance. Orr
et al.[10] also reviewed that alterations in tubulin
composition expression were associated with pacli-
taxel resistance.Wealso confirmed theup-regulation of
some tubulin b-6 (3.53-fold), 2 (2.22-fold), and 4
(2.13-fold) in PC-3-TxR cells by cDNA microarray
analysis. However, overexpression of bIII isotype in
human prostate carcinoma cells by stable transfection
failed to confer antimicrotubule drug resistance to
these cells [31]. Interestingly, overexpression of tubulin
b are relatedwithpoor prognosis and resistance [32].At
least overexpression of tubulin bs may be thought with
a good marker predicting with reactivity for paclitaxel
and prognosis. Wewill investigate if overexpression of
tubulin bs causes paclitaxel resistance and progression
in PC-3 cells.
Paclitaxel is known to repress influx of calcium into
cytoplasm [33,34]. Reduction of calcium-associated
proteins expression may be a cause of repression of
calcium influx by paclitaxel and may not be a
mechanism of paclitaxel resistance. However, calcium
dynamics which is associated with microtubule poly-
merization is important factor for paclitaxel-resistance.
Moreover, altered intracellular calcium homeostasis
may contribute to the paclitaxel-resistant phenotype
[35]. Microarray analysis in this study revealed a
decline of S100A8/S100A9 expression in PC-3-TxR
cells compared with parent PC-3 cells. Calcium-
induced complexes of S100A8 and S100A9 have been
shown to colocalize with microtubules during activa-
tion of monocytes. They directly bind to tubulin and
promote tubulin polymerization in a calcium-depen-
dent manner [36]. Then failure of tetramer formation
was associated with a lack of functional activity of
S100A8/S100A9 complexes in promoting the forma-
tion of microtubules [37]. A decline of S100A8/S100A9
expression would also inhibit the formation of micro-
tubules. Therefore, since paclitaxel cannot stabilize the
formation of microtubules due to a decline of S100A8/
S100A9 expression in PC-3-TxR cells, paclitaxel might
not be able to show effect as an anticancer drug in
resistant cells.
In conclusions, after we established paclitaxel-
resistant hormone refractory PCa cell lines, we com-
pared resistant cells with parent cells. This comparison
will make it more possible to identify the genes which
cause paclitaxel resistance except MDR-1. Not only
MDR-1 gene but also many genes were up-regulated
and down-regulated. We have to still distinguish the
genes that are responsible for resistance from the genes
that are regulated as a result one by one. Nevertheless,
identification of these genes will be useful for thinking
strategies using taxanes to individual hormone refrac-
tory PCa.
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